Skip to content

A Multicenter, single-blind, randomized, parallel-group trial comparing stapler closure with Clip on Staple method with stapler closure alone during Distal Pancreatectomy

A Multicenter, single-blind, randomized, parallel-group trial comparing stapler closure with Clip on Staple method with stapler closure alone during Distal Pancreatectomy - CLIP-DP trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000042217
Enrollment
188
Registered
2020-11-01
Start date
2020-11-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who undergo distal pancreatectomy

Interventions

Reinforced stapler + Clip on Staple method Reinforced stapler

Sponsors

Kyushu Study group of Clinical Cancer (KSCC)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Elective distal pancreatectomy(open/laparoscopic/laparoscope-assisted/robot assisted) for disease of the pancreatic body and tail. *Spleen-preserving DP, RAMPS, DP with combined resection of surrounding organs(e.g. DP-CAR) are also included. 2)The thickness of the pancreatic cutting line on preoperative images are equal or less than 20mm. 3)ECOG Performance Status is 0-1. 4)Aged 20 years old or older. 5)Function of the major organs are maintained. 6)Following criteria are fulfilled in the recent laboratory tests within 30 days from registration. A)White Blood Cells >= 2,500/mm3 B)Haemoglobin levels >= 9.0 g/dL C)Platelet counts >= 100,000/mm3 D)Albumin levels >= 3.0 g/dL E)Total Bilirubin levels <= 2.0 mg/dL F)Creatinine levels <= 2.0 mg/dL 7)Sufficient understanding of the study to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1)Superior mesenteric vein or portal vein invasion on preoperative images. 2)Planned cutting line of the pancreas is right side of the superior mesenteric vein or portal vein. 3)Use of stapling device is inappropriate. 4)Presence of inoperable factors such as peritoneal dissemination, invasion to major vessels, or liver metastases. 5)Emergent cases. 6)Severe cardiac diseases(NYHA>=3). 7)Need for daily oxygen supply due to severe pulmonary diseases. 8)On maintenance hemodialysis due to chronic renal failure. 9)Allergy to metals. 10)Considered as inappropriate by attending physician.

Design outcomes

Primary

MeasureTime frame
The incidence of clinically-relevant pancreatic fistula(ISGPF GradeB/C) or death due to any cause within 30 days after surgery.

Secondary

MeasureTime frame
<Secondary endpoints> The incidence of following complications within 30 days after surgery. _Pancreatic fistula(ISGPF BL/GradeB/C) _Postpancreatectomy hemorrhage(PPH) _Intra-abdominal abscess _Delayed gastric emptying _Complications(Clavien-Dindo classification, CD>=Grade3) _Percutaneous or Endoscopic drainage Duration of drainage tube placement Postoperative hospital stay Operative time/Blood loss Re-operation within 90 days Mortality within 90 days <Exploratory endpoints> The incidence of clinically-relevant pancreatic fistula according to the thickness of the pancreas(<=12mm/>12mm) The incidence of pancreatic parenchymal injury after clipping(Central review of intraoperative photography)

Countries

Japan

Contacts

Public ContactMizuki Ninomiya

Fukuoka City Hospital Department of Liver Surgery

nino0401@icloud.com092-632-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026